NM-9308

N/A

Report date: 2025/01/26 17:30:31

Base Information

Drug NameNM-9308

Drug Alias Nameanti-factor B monoclonal antibody (NovelMed Therapeutics)complement factor B inhibitor (NovelMed Therapeutics)BikaciomabBikaciomab (NovelMed Therapeutics)NM-9308

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized

Mechanisms of ActionComplement factor B inhibitors

TargetsComplement factor B

Therapy Area/IndicationsMacular Degeneration

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesNovelMed Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesNovelMed Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsMacular Degeneration

Inactive IndicationsN/A

Other Information

ATC CodeN/A